David Nickeson
Pulmonary Disease · Texas City, TXNPI 1831151208
Payments from drug & device makers
Across 333 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$942
- Insmed, Inc.$806
- Boehringer Ingelheim$617
- Actelion Pharmaceuticals US, Inc.$569
- Electromed, Inc.$478
- plus $3K from 18 others
What the payments were for
- Food & beverage$7,06199%
- Education$901%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 60 | $1,149 |
| GSK | 46 | $942 |
| Insmed, Inc. | 37 | $806 |
| Boehringer Ingelheim | 25 | $617 |
| Actelion Pharmaceuticals US, Inc. | 19 | $569 |
| Electromed, Inc. | 28 | $478 |
| Sunovion Pharmaceuticals Inc. | 25 | $416 |
| Mylan Specialty L.p. | 18 | $357 |
| Regeneron Healthcare Solutions, Inc. | 14 | $337 |
| Harmony Biosciences LLC | 6 | $210 |
| AbbVie(2 entities) | 9 | $192 |
| Philips North America LLC | 12 | $164 |
| Pulmonx Corporation | 1 | $147 |
| Grifols USA, LLC | 5 | $135 |
| Mallinckrodt Hospital Products Inc. | 7 | $135 |
| Amgen | 1 | $102 |
| Shionogi Inc | 4 | $88 |
| Jazz Pharmaceuticals Inc. | 4 | $80 |
| Sanofi | 3 | $56 |
| Gilead | 2 | $44 |
| Bayer | 2 | $42 |
| United Therapeutics Corporation | 2 | $32 |
| Circassia Inc. | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TEZSPIRE$205
- CHARTIS CATHETER$147
- ZEPHYR DELIVERY CATHETER$147
- ZEPHYR ENDOBRONCHIAL VALVE$147
- PULMONX CHARTIS TABLET CONSOLE$147
- Arikayce$126
- OFEV$125
- Wakix$125
How this compares
$7,151 in reported general payments places this provider in the 65th percentile of 904 pulmonary disease providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,829 |
| Montelukast Sodium | 19 | $228 |
| Furosemide | 16 | $166 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere | $1,149 | $7,82912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Texas City
- Charles AndrewsSan Antonio$17M
- Ivan RosasHouston$13.8M
- Shahrukh KureishyMcKinney$12.4M
- Raksha JainDallas$3.4M
- Kelly ChinDallas$2.7M
- Julie PhilleyTyler$2.4M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.